Current and emerging treatment options for Wiskott–Aldrich syndrome

References

• Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994;78:635-44
   PubMed Web of Science ®Google Scholar
• Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol 2000;20:477-85
   PubMed Web of Science ®Google Scholar
• Perry GSIII, Spector BD, Schuman LM, et al. The wiskott-aldrich syndrome in the United States and Canada (1892-1979). J Pediatr 1980;97:72-8
   PubMed Web of Science ®Google Scholar
• Mahlaoui N, Pellier I, Mignot C, et al. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. Blood 2013;121:1510-16
   PubMed Web of Science ®Google Scholar
• Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function. Dis Markers 2010;29:157-75
   PubMed Web of Science ®Google Scholar
• Catucci M, Castiello MC, Pala F, et al. Autoimmunity in Wiskott-Aldrich syndrome: an unsolved enigma. Front Immunol 2012;3:209
   PubMed Web of Science ®Google Scholar
• Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci 2013;1285:26-43
   PubMed Web of Science ®Google Scholar
• Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010;10:182-92
   PubMed Web of Science ®Google Scholar
• Cleland SY, Siegel RM. Wiskott-Aldrich Syndrome at the nexus of autoimmune and primary immunodeficiency diseases. FEBS Lett 2011;585:3710-14
   PubMed Web of Science ®Google Scholar
• Kreishman-Deitrick M, Goley ED, Burdine L, et al. NMR analyses of the activation of the Arp2/3 complex by neuronal Wiskott-Aldrich syndrome protein. Biochemistry 2005;44:15247-56
   PubMed Web of Science ®Google Scholar
• Panchal SC, Kaiser DA, Torres E, et al. A conserved amphipathic helix in WASP/Scar proteins is essential for activation of Arp2/3 complex. Nat Struct Biol 2003;10:591-8
   PubMedGoogle Scholar
• Kim AS, Kakalis LT, Abdul-Manan N, et al. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 2000;404:151-8
   PubMed Web of Science ®Google Scholar
• Lim RP, Misra A, Wu Z, Thanabalu T. Analysis of conformational changes in WASP using a split YFP. Biochem Biophys Res Commun 2007;362:1085-9
   PubMed Web of Science ®Google Scholar
• Martinez-Quiles N, Rohatgi R, Anton IM, et al. WIP regulates N-WASP-mediated actin polymerization and filopodium formation. Nat Cell Biol 2001;3:484-91
   PubMedGoogle Scholar
• Chou HC, Anton IM, Holt MR, et al. WIP regulates the stability and localization of WASP to podosomes in migrating dendritic cells. Curr Biol 2006;16:2337-44
   PubMedGoogle Scholar
• de la Fuente MA, Sasahara Y, Calamito M, et al. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Nat Acad Sci 2007;104:926-31
   PubMed Web of Science ®Google Scholar
• Sasahara Y, Rachid R, Byrne MJ, et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell 2002;10:1269-81
   PubMed Web of Science ®Google Scholar
• Tsuboi S, Meerloo J. Wiskott-Aldrich syndrome protein is a key regulator of the phagocytic cup formation in macrophages. J Biol Chem 2007;282:34194-203
   PubMed Web of Science ®Google Scholar
• Blanchoin L, Amann KJ, Higgs HN, et al. Direct observation of dendritic actin filament networks nucleated by Arp2/3 complex and WASP/Scar proteins. Nature 2000;404:1007-11
   PubMed Web of Science ®Google Scholar
• Badour K, Zhang J, Shi F, et al. Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J Exp Med 2004;199:99-112
   PubMed Web of Science ®Google Scholar
• Cory GO, Garg R, Cramer R, Ridley AJ. Phosphorylation of tyrosine 291 enhances the ability of WASp to stimulate actin polymerization and filopodium formation. Wiskott-Aldrich Syndrome protein. J Biol Chem 2002;277:45115-21
   PubMed Web of Science ®Google Scholar
• Kato M, Miki H, Imai K, et al. Wiskott-Aldrich syndrome protein induces actin clustering without direct binding to Cdc42. J Biol Chem 1999;274:27225-30
   PubMed Web of Science ®Google Scholar
• Cory GO, Cramer R, Blanchoin L, Ridley AJ. Phosphorylation of the WASP-VCA domain increases its affinity for the Arp2/3 complex and enhances actin polymerization by WASP. Mol Cell 2003;11:1229-39
   PubMedGoogle Scholar
• Torres E, Rosen MK. Contingent phosphorylation/dephosphorylation provides a mechanism of molecular memory in WASP. Mol Cell 2003;11:1215-27
   PubMedGoogle Scholar
• Blundell MP, Bouma G, Metelo J, et al. Phosphorylation of WASp is a key regulator of activity and stability in vivo. Proc Natl Acad Sci USA 2009;106:15738-43
   PubMed Web of Science ®Google Scholar
• Reicher B, Joseph N, David A, et al. Ubiquitylation-dependent negative regulation of WASp is essential for actin-cytoskeleton dynamics. Mol Cell Biol 2012;32(15):3153-63
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Sasahara Y, Ramesh N, et al. T-cell receptor ligation causes Wiskott-Aldrich syndrome protein degradation and F-actin assembly downregulation. J Allergy Clin Immunol 2013;132:648-55
   PubMed Web of Science ®Google Scholar
• Parolini O, Berardelli S, Riedl E, et al. Expression of Wiskott-Aldrich syndrome protein (WASP) gene during hematopoietic differentiation. Blood 1997;90:70-5
   PubMed Web of Science ®Google Scholar
• Snapper SB, Takeshima F, Anton I, et al. N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol 2001;3:897-904
   PubMed Web of Science ®Google Scholar
• Cotta-de-Almeida V, Westerberg L, Maillard MH, et al. Wiskott Aldrich syndrome protein (WASP) and N-WASP are critical for T cell development. Proc Natl Acad Sci USA 2007;104:15424-9
   PubMed Web of Science ®Google Scholar
• Sadhukhan S, Sarkar K, Taylor M, et al. Nuclear role of WASp in gene transcription is uncoupled from its ARP2/3-dependent cytoplasmic role in actin polymerization. J Immunol 2014;193:150-60
   PubMed Web of Science ®Google Scholar
• Looi CY, Sasahara Y, Watanabe Y, et al. The open conformation of WASP regulates its nuclear localization and gene transcription in myeloid cells. Int Immunol 2014;26:341-52
   PubMed Web of Science ®Google Scholar
• Taylor MD, Sadhukhan S, Kottangada P, et al. Nuclear role of WASp in the pathogenesis of dysregulated TH1 immunity in human Wiskott-Aldrich syndrome. Sci Transl Med 2010;2:37ra44
   PubMed Web of Science ®Google Scholar
• Abinun M, Mikuska M, Filipovic B. Infantile cortical hyperostosis associated with the Wiskott-Aldrich syndrome. Eur J Pediatr 1988;147:518-19
   PubMed Web of Science ®Google Scholar
• Adriani M, Jones KA, Uchiyama T, et al. Defective inhibition of B-cell proliferation by Wiskott-Aldrich syndrome protein-deficient regulatory T cells. Blood 2011;117:6608-11
   PubMed Web of Science ®Google Scholar
• Marangoni F, Trifari S, Scaramuzza S, et al. WASP regulates suppressor activity of human and murine CD4+CD25+FOXP3+ natural regulatory T cells. J Experim Med 2007;204:369-80
   PubMed Web of Science ®Google Scholar
• Park JY, Shcherbina A, Rosen FS, et al. Phenotypic perturbation of B cells in the Wiskott-Aldrich syndrome. Clin Exp Immunol 2005;139:297-305
   PubMed Web of Science ®Google Scholar
• Recher M, Burns SO, de la Fuente MA, et al. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood 2012;119:2819-28
   PubMed Web of Science ®Google Scholar
• Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 2008;112:4139-47
   PubMed Web of Science ®Google Scholar
• Simon KL, Anderson SM, Garabedian EK, et al. Molecular and phenotypic abnormalities of B lymphocytes in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2014;133:896-9
   PubMed Web of Science ®Google Scholar
• Castiello MC, Bosticardo M, Pala F, et al. Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. J Autoimmun 2014;50:42-50
   PubMed Web of Science ®Google Scholar
• Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 2011;208:2033-42
   PubMed Web of Science ®Google Scholar
• Schurman SH, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol 2003;15:446-53
   PubMed Web of Science ®Google Scholar
• Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994;125:876-85
   PubMed Web of Science ®Google Scholar
• Mantadakis E, Sawalle-Belohradsky J, Tzanoudaki M, et al. X-linked thrombocytopenia in three males with normal sized platelets due to novel WAS gene mutations. Pediatr Blood Cancer 2014;61:2305-6
   PubMed Web of Science ®Google Scholar
• Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004;103:456-64
   PubMed Web of Science ®Google Scholar
• Lutskiy MI, Rosen FS, Remold-O’Donnell E. Genotype-proteotype linkage in the Wiskott-Aldrich syndrome. J Immunol 2005;175:1329-36
   PubMed Web of Science ®Google Scholar
• Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003;111:e622-7
   PubMed Web of Science ®Google Scholar
• Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003;111:e622-7
   PubMed Web of Science ®Google Scholar
• Akman IO, Ostrov BE, Neudorf S. Autoimmune manifestations of the Wiskott-Aldrich syndrome. Semin Arthritis Rheum 1998;27:218-25
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nikolov NP, Ueno K, et al. Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency. Clin Immunol 2012;142:160-6
   PubMed Web of Science ®Google Scholar
• Strom TS. The thrombocytopenia of WAS: a familial form of ITP? Immunol Res 2009;44:42-53
   PubMed Web of Science ®Google Scholar
• Semple JW, Siminovitch KA, Mody M, et al. Flow cytometric analysis of platelets from children with the Wiskott-Aldrich syndrome reveals defects in platelet development, activation and structure. Br J Haematol 1997;97:747-54
   PubMed Web of Science ®Google Scholar
• Pellier I, Dupuis GS, Loisel D, et al. Occurrence of aortic aneurysms in 5 cases of Wiskott-Aldrich syndrome. Pediatrics 2011;127:e498-504
   Google Scholar
• Tran H, Nourse J, Hall S, et al. Immunodeficiency-associated lymphomas. Blood Rev 2008;22:261-81
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Kamachi Y, Imai K, et al. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia. Pediatr Blood Cancer 2013;60:836-41
   PubMed Web of Science ®Google Scholar
• Sano H, Kobayashi R, Suzuki D, et al. Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia. Int J Hematol 2012;96:279-83
   PubMed Web of Science ®Google Scholar
• Ochs HD, Filipovich AH, Veys P, et al. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009;15:84-90
   PubMed Web of Science ®Google Scholar
• Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 1997;90:2680-9
   PubMed Web of Science ®Google Scholar
• Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006;108:2182-9
   PubMed Web of Science ®Google Scholar
• Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001;27:313-17
   PubMed Web of Science ®Google Scholar
• Moulding DA, Moeendarbary E, Valon L, et al. Excess F-actin mechanically impedes mitosis leading to cytokinesis failure in X-linked neutropenia by exceeding Aurora B kinase error correction capacity. Blood 2012;120:3803-11
   PubMed Web of Science ®Google Scholar
• Kawai S, Minegishi M, Ohashi Y, et al. Flow cytometric determination of intracytoplasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations. J Immunol Methods 2002;260:195-205
   PubMed Web of Science ®Google Scholar
• Yamada M, Ohtsu M, Kobayashi I, et al. Flow cytometric analysis of Wiskott-Aldrich syndrome (WAS) protein in lymphocytes from WAS patients and their familial carriers. Blood 1999;93:756-7
   PubMed Web of Science ®Google Scholar
• MacCarthy-Morrogh L, Gaspar HB, Wang YC, et al. Absence of expression of the Wiskott-Aldrich syndrome protein in peripheral blood cells of Wiskott-Aldrich syndrome patients. Clin Immunol Immunopathol 1998;88:22-7
   PubMedGoogle Scholar
• Imai K, Nonoyama S, Ochs HD. WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype. Curr Opin Allergy Clin Immunol 2003;3:427-36
   PubMedGoogle Scholar
• Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004;104:4010-19
   PubMed Web of Science ®Google Scholar
• Lanzi G, Moratto D, Vairo D, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med 2012;209(1):29-34
   PubMed Web of Science ®Google Scholar
• Luthi JN, Gandhi MJ, Drachman JG. X-linked thrombocytopenia caused by a mutation in the Wiskott-Aldrich syndrome (WAS) gene that disrupts interaction with the WAS protein (WASP)-interacting protein (WIP). Exp Hematol 2003;31:150-8
   PubMed Web of Science ®Google Scholar
• Rong SB, Vihinen M. Structural basis of Wiskott-Aldrich syndrome causing mutations in the WH1 domain. J Mol Med 2000;78:530-7
   PubMed Web of Science ®Google Scholar
• Stewart DM, Tian L, Nelson DL. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. J Immunol 1999;162:5019-24
   PubMed Web of Science ®Google Scholar
• Volkman BF, Prehoda KE, Scott JA, et al. Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott-Aldrich Syndrome. Cell 2002;111:565-76
   PubMed Web of Science ®Google Scholar
• Worth AJ, Metelo J, Bouma G, et al. Disease-associated missense mutations in the EVH1 domain disrupt intrinsic WASp function causing dysregulated actin dynamics and impaired dendritic cell migration. Blood 2013;121:72-84
   PubMed Web of Science ®Google Scholar
• Greer WL, Shehabeldin A, Schulman J, et al. Identification of WASP mutations, mutation hotspots and genotype-phenotype disparities in 24 patients with the Wiskott-Aldrich syndrome. Hum Genet 1996;98:685-90
   PubMed Web of Science ®Google Scholar
• Buchbinder D, Nadeau K, Nugent D. Monozygotic twin pair showing discordant phenotype for X-linked thrombocytopenia and Wiskott-Aldrich syndrome: a role for epigenetics? J Clin Immunol 2011;31:773-7
   PubMed Web of Science ®Google Scholar
• Wengler G, Gorlin JB, Williamson JM, et al. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood 1995;85:2471-7
   PubMed Web of Science ®Google Scholar
• Boonyawat B, Dhanraj S, Al AF, et al. Combined de-novo mutation and non-random X-chromosome inactivation causing Wiskott-Aldrich syndrome in a female with thrombocytopenia. J Clin Immunol 2013;33:1150-5
   PubMed Web of Science ®Google Scholar
• Conley ME, Wang WC, Parolini O, et al. Atypical Wiskott-Aldrich syndrome in a girl. Blood 1992;80:1264-9
   PubMed Web of Science ®Google Scholar
• Lutskiy MI, Sasahara Y, Kenney DM, et al. Wiskott-Aldrich syndrome in a female. Blood 2002;100:2763-8
   PubMed Web of Science ®Google Scholar
• Parolini O, Ressmann G, Haas OA, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med 1998;338:291-5
   PubMed Web of Science ®Google Scholar
• Davis BR, Candotti F. Revertant somatic mosaicism in the Wiskott-Aldrich syndrome. Immunol Res 2009;44:127-31
   PubMed Web of Science ®Google Scholar
• Davis BR, Yan Q, Bui JH, et al. Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. Clin Immunol 2010;135:72-83
   PubMed Web of Science ®Google Scholar
• Lutskiy MI, Park JY, Remold SK, et al. Evolution of highly polymorphic T cell populations in siblings with the Wiskott-Aldrich Syndrome. PLoS ONE 2008;3:e3444
   Google Scholar
• Trifari S, Scaramuzza S, Catucci M, et al. Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. J Allergy Clin Immunol 2010;125:439-48
   PubMed Web of Science ®Google Scholar
• Lutskiy MI, Beardsley DS, Rosen FS, Remold-O’Donnell E. Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome. Blood 2005;106:2815-17
   PubMed Web of Science ®Google Scholar
• Gallego MD, Santamaria M, Pena J, Molina IJ. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood 1997;90:3089-97
   PubMed Web of Science ®Google Scholar
• Vermi W, Blanzuoli L, Kraus MD, et al. The spleen in the Wiskott-Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. Am J Surg Pathol 1999;23:182-91
   PubMed Web of Science ®Google Scholar
• Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63
   PubMed Web of Science ®Google Scholar
• Conley ME, Saragoussi D, Notarangelo L, et al. An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol 2003;109:272-7
   PubMed Web of Science ®Google Scholar
• Litzman J, Jones A, Hann I, et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child 1996;75:436-9
   PubMed Web of Science ®Google Scholar
• Mathew P, Conley ME. Effect of intravenous gammaglobulin (IVIG) on the platelet count in patients with Wiskott-Aldrich syndrome. Pediatr Allergy Immunol 1995;6:91-4
   PubMed Web of Science ®Google Scholar
• Gerrits AJ, Leven E, Frelinger AL, et al. Effects of eltrombopag on thrombocytopenia, platelet function and bleeding in patients with wiskott-aldrich syndrome/ x-linked thrombocytopenia. Am Soc Haematol 2013
   Google Scholar
• Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011;118:1675-84
   PubMed Web of Science ®Google Scholar
• Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008;111:439-45
   PubMed Web of Science ®Google Scholar
• Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med 1978;298:921-7
   PubMedGoogle Scholar
• Kapoor N, Kirkpatrick D, Blaese RM, et al. Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. Blood 1981;57:692-6
   PubMed Web of Science ®Google Scholar
• Friedrich W, Schutz C, Schulz A, et al. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors. Immunol Res 2009;44:18-24
   PubMed Web of Science ®Google Scholar
• Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006;135:362-6
   PubMed Web of Science ®Google Scholar
• Pai SY, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006;38:671-9
   PubMed Web of Science ®Google Scholar
• Shin CR, Kim MO, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant 2012;47:1428-35
   PubMed Web of Science ®Google Scholar
• Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010;126:602-10
   PubMed Web of Science ®Google Scholar
• Mitchell R, Nivison-Smith I, Anazodo A, et al. Outcomes of hematopoietic stem cell transplantation in primary immunodeficiency: a report from the Australian and New Zealand Children’s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Biol Blood Marrow Transplant 2013;19:338-43
   PubMed Web of Science ®Google Scholar
• Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361:553-60
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the international bone marrow transplant registry and the national marrow donor program. Blood 2001;97:1598-603
   PubMed Web of Science ®Google Scholar
• Oshima K, Imai K, Albert MH, et al. Hematopoietic stem cell transplantation for X-linked thrombocytopenia with mutations in the WAS gene. J Clin Immunol 2014. [Epub ahead of print]
   Google Scholar
• Morio T, Atsuta Y, Tomizawa D, et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol 2011;154:363-72
   PubMed Web of Science ®Google Scholar
• Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood 2014;124:822-6
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pende D, Mingari MC, et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013;4:15
   PubMed Web of Science ®Google Scholar
• Kharya G, Nademi Z, Leahy TR, et al. Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2014;134:1199-201
   PubMed Web of Science ®Google Scholar
• Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005;105:879-85
   PubMed Web of Science ®Google Scholar
• Chiesa R, Veys P. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol 2012;8:255-66
   PubMed Web of Science ®Google Scholar
• Gungor T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014;383:436-48
   PubMed Web of Science ®Google Scholar
• Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011;117:4367-75
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Ariga T, Yamada M, et al. Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression. Blood 2002;100:1208-14
   PubMed Web of Science ®Google Scholar
• Haines HL, Bleesing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant 2015;21:288-92
   PubMed Web of Science ®Google Scholar
• Adriani M, Aoki J, Horai R, et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol 2007;124:41-8
   PubMed Web of Science ®Google Scholar
• Humblet-Baron S, Sather B, Anover S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Investig 2007;117:407-18
   PubMed Web of Science ®Google Scholar
• Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4+CD25+Foxp3+ regulatory T cells. The J Exper Med 2007;204:381-91
   PubMed Web of Science ®Google Scholar
• Astrakhan A, Ochs HD, Rawlings DJ. Wiskott-Aldrich syndrome protein is required for homeostasis and function of invariant NKT cells. J Immunol 2009;182:7370-80
   PubMed Web of Science ®Google Scholar
• Locci M, Draghici E, Marangoni F, et al. The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med 2009;206:735-42
   PubMed Web of Science ®Google Scholar
• Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989;321:784-9
   PubMed Web of Science ®Google Scholar
• Kamani NR, Kumar S, Hassebroek A, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2011;17:1783-9
   PubMed Web of Science ®Google Scholar
• Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011;155:377-85
   PubMed Web of Science ®Google Scholar
• Eapen M, Ahn KW, Orchard PJ, et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant 2012;18:1438-45
   PubMed Web of Science ®Google Scholar
• Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther 2006;8:390-5
   PubMed Web of Science ®Google Scholar
• Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med 2014;6:227ra33
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011;3:97ra79
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363:355-64
   PubMed Web of Science ®Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013;341:1233151
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Gaspar HB, Blondeau J, et al. Clinical efficacy of gene therapy for severe wiskott-aldrich syndrome. JAMA 2015;313(15):1550-63
   PubMed Web of Science ®Google Scholar
• Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010;115:3231-8
   PubMed Web of Science ®Google Scholar
• Sarkar K, Sadhukhan S, Han SS, Vyas YM. Disruption of hSWI/SNF complexes in T cells by WAS mutations distinguishes X-linked thrombocytopenia from Wiskott-Aldrich syndrome. Blood 2014;124:3409-19
   PubMed Web of Science ®Google Scholar
• Corash L, Shafer B, Blaese RM. Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome. Blood 1985;65:1439-43
   PubMed Web of Science ®Google Scholar
• Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood 1993;82:2961-6
   PubMed Web of Science ®Google Scholar
• Pershin ES, Viktorova EA, Osipova EY, et al. Thrmobopoietin (TPO) receptor agonists romiplostim is effective in treatment of thrombocytopenia in Wiskott Aldrich Syndrome. 16th Biennial meeting of the European Society of Immunodefiencies, Prague, 2014
   Google Scholar
• Massaad MJ, Ramesh N, Le BS, et al. A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding. J Allergy Clin Immunol 2011;127:998-1005
   PubMed Web of Science ®Google Scholar
• Kahraman S, Beyazyurek C, Yesilipek MA, et al. Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching. Reprod Biomed Online 2014;29:340-51
   PubMed Web of Science ®Google Scholar
• Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006;117:725-38
   PubMed Web of Science ®Google Scholar